CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Jacob Leach

President & Chief Executive Officer, Dexcom

Search every verified Jacob Leach interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Jacob Leach, who became CEO of Dexcom on January 1, 2026, has been discussing the company's recent clinical data, product development, and efforts to address user concerns. On the company's Q2 2026 earnings call, he cited results from the Connect study, a randomized controlled trial in people with type 2 diabetes not using insulin, which he said demonstrated meaningful health outcomes and economic savings. He also mentioned a real-world evidence study with CVS Health that showed reductions in diabetes-related hospitalizations and microvascular complications, and discussed Dexcom's potential to screen for pre-diabetes under its Tempo program. In interviews following the ADA conference, Leach discussed the company's plans for the next-generation G8 sensor, which he said would use new electronics and an algorithm to adapt the sensor signal over time and improve accuracy. He acknowledged that Dexcom had lost trust in the community following issues with the G7 sensor and described the formation of a customer advisory council to gather feedback, noting that the organization could improve communication about product changes. He also mentioned Dexcom's acquisition of Nutrisense, a nutritional coaching company, and stated the company's goal of developing the first continuous glucose monitor approved for inpatient hospital use, as well as work on sensing additional analytes such as potassium.

Recent appearances

Verified interview transcripts

Notable quotes

“I believe it makes Dexcom one of the most compelling investment opportunities in health care today. And really, this plan has just get started.”

“There are three key drivers that are going to define the next phase of Dexcom's journey. First, we have an advanced product portfolio that is focused on meeting valuable, distinct, highly important things for our customers. Second, the clinical and economic value we produce is going to significantly continue to expand access for people to CGM. And we believe that that access is going to continue to grow at a rate fas”

“There's over 600 million people in the world that have diabetes. Very few of them actually have access to CGM technology, and our goal is to continue improving it, lowering the cost, and expanding global access.”

“One of the unique differences here is when it comes to drugs there are a lot of rules around advertising and side effects, but with CGM the only real side effect is better glucose. I'm aware of the FDA letter, but I don't think it necessarily applies to us — we do a lot of direct-to-consumer advertising to make sure people are aware that CGM exists and can ask their doctor about coverage.”

“We have a very large clinical trial running right now in people with type two who don't use insulin specifically, a randomized control trial to show the outcomes that can be generated by wearing a Dexcom CGM for that population. And I think that would be an important evidence to use globally not just here for the United States to continue to get more access and coverage because CGM saves money in the first year.”

Other executives at Dexcom

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →